) recently announced positive results from the PALACE 4 study on
apremilast. The study is evaluating apremilast (20 mg and 30 mg),
a novel, oral small-molecule inhibitor of phosphodiesterase 4
(PDE4), in patients suffering from psoriatic arthritis.
Results from the phase III study showed that apremilast
achieved statistical significance for ACR 20 at week 16 in
psoriatic arthritis patients across both dosage strengths.
Results also revealed that the candidate showed benefit over
placebo in other secondary objectives of the study. We note that
the 52-week PALACE 4 study is currently underway.
Besides the PALACE 4 study, the PALACE program also consists
of three more phase III studies (PALACE 1, PALACE 2 and PALACE 3)
on apremilast in the psoriatic arthritis indication. We remind
investors that Celgene presented encouraging data from the
PALACE-2 and PALACE-3 studies in Sep 2012 and from the PALACE 1
study in Nov 2012. Top-line results from PALACE 3 study and
52-week results from PALACE 1 study are expected in June this
Earlier this year, Celgene submitted regulatory submissions
for the approval of apremilast (psoriatic arthritis) in the US
and Canada, based on the positive results from PALACE 1, 2 and 3
We note that apart from psoriatic arthritis, apremilast is
also being developed for the treatment of psoriasis, ankylosing
spondylitis, and Behçet's disease.
Celgene intends to seek US approval for the psoriasis
indication in the latter half of the year. European approval of
psoriatic arthritis and psoriasis indications is expected to be
sought in the second half of the year on a combined basis.
Celgene, a biopharmaceutical company, currently carries a
Zacks Rank #2 (Buy). Other biopharma stocks, such as
) are comparatively well placed and carry a Zacks Rank #1 (Strong
ATHERSYS INC (ATHX): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
XOMA CORP (XOMA): Free Stock Analysis Report
To read this article on Zacks.com click here.